Drug Trial Radar · NCT04333147
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,916
Actual
Start
May 12, 2020
Primary completion
Feb 24, 2023
Study completion Feb 24, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RA is a chronic, systemic inflammatory autoimmune disease which requires treatment for a long time period, hence it is important to study the long-term safety and efficacy of the continuous treatment with GSK3196165 over several years. This is a Phase 3, multicenter, parallel group treatment and long-term extension study primarily to assess safety with efficacy assessment as a secondary objective. Adult participants with RA who have completed the treatment phase of a qualifying GSK3196165 clinical studies (Phase 3 studies contRAst 1 (201790: NCT03980483), contRAst 2 (201791: NCT03970837) and contRAst 3 (202018: NCT04134728) and who, in investigator's judgement will benefit from extended treatment with GSK3196165 will be included in this study (contRAst X \[209564: NCT04333147\]). Participants will continue to receive the same background conventional synthetic disease modifying anti-rheumatic drug(s) \[csDMARD(s)\] treatment as they received in their qualifying study. Eligible participants will be enrolled to receive weekly GSK3196165 90 milligrams (mg) or 150 mg by subcutaneous (SC) injection. The anticipated study duration is approximately 4 years which will enable participants to receive treatment with GSK3196165 until it is expected to become commercially available. Approximately 3000 participants from the qualifying studies will participate in this long-term extension study
Conditions
- Arthritis, Rheumatoid
Interventions
Otilimab (GSK3196165)Biological
GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
csDMARD(s)Drug
Stable dose of csDMARD(s) as standard of care (SoC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)Time frame: Up to approximately 145 Weeks
- Change From Baseline in Hematology Parameter of Platelet Count at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in Hematology Parameter of Platelet Count at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in Hematology Parameter of Platelet Count at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in Hematology Parameter of Platelet Count at Week 144Time frame: Baseline (Day 01) and Week 144
- Change From Baseline in Hematology Parameter of Hemoglobin at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in Hematology Parameter of Hemoglobin at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in Hematology Parameter of Hemoglobin at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in Hematology Parameter of Hemoglobin at Week 144Time frame: Baseline (Day 01) and Week 144
- Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 144Time frame: Baseline (Day 01) and Week 144
- Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 144Time frame: Baseline (Day 01) and Week 144
- Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 144Time frame: Baseline (Day 01) and Week 144
- Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry AbnormalitiesTime frame: Up to approximately 145 Weeks
- Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 24Time frame: Baseline (Day 01) and Week 24
- Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 48Time frame: Baseline (Day 01) and Week 48
- Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 96Time frame: Baseline (Day 01) and Week 96
- Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 144Time frame: Baseline (Day 01) and Week 144
Locations
375 sites in 27 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anniston, Alabama
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Gilbert, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Covina, California
GSK Investigational Site
Poway, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Whittier, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Fort Collins, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Brandon, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Daytona Beach, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
New Port Richey, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Palmetto Bay, Florida
GSK Investigational Site
Tamarac, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Idaho Falls, Idaho
GSK Investigational Site
Skokie, Illinois
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Wichita, Kansas
Showing 40 of 375 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.